Krogager et al. 6 recently demonstrated a U-shaped relation between sK levels and mortality in acute HF patients. Likewise, Aldahl et al. 7 most recently reported that even high and low sK levels within the normal range of sK were associated with a significantly increased short-term risk of death in chronic HF patients. In the report by Aldahl et al., however, information on EF for each HF patients was not available. Therefore, they were not able to subdivide HF patients according to HFrEF or HFpEF. 7 For HFpEF, which is a problem all over the world, establishment of risk stratification for future cardiovascular events is clinically important. In the present study, we examined the importance of monitoring sK levels and proposed optimal sK levels in HFpEF patients after treatments for HF.
METHODS

Study subjects
We retrospectively investigated 948 consecutive patients with HF who were hospitalized in the Kumamoto University Hospital between January 2007 and September 2013 and recorded each patient's medical history and relevant clinical characteristics. We excluded 442 patients for the following reasons: severe valvular disease (n = 118), chronic renal failure and undergoing hemodialysis (n = 65), systemic inflammatory disease (n = 5), acute renal failure with dehydration (n = 1), and failure to meet the diagnostic criteria for HFpEF described below (including HFrEF) (n = 251). Finally, the remaining 506 HFpEF patients were enrolled in this study ( Figure 1 ).
Ethics statement, clinical parameters, and echocardiography
Detailed ethics statement, clinical parameters, and echocardiography are available in the Supplementary Material.
Biochemistry
Both compensated and acute decompensated HF patients were registered in the present study. At the hospital discharge point when patients were in a compensated condition after implementation of medical therapy for HF, venous samples were collected in a stable, fasting state in the early morning to measure sK and other biochemical marker levels. The main purpose of the present study was to investigate the relationship between the occurrence of future cardiovascular events and sK levels in the HFpEF patients who were optimally treated and were already in a stable condition. Detailed other blood sampling methods are available in the Supplementary Material.
Definition of HFpEF
HFpEF was clinically defined according to the European Society of Cardiology task force criteria as follows: (i) symptoms or signs of HF; (ii) normal or mildly reduced LVEF (LVEF > 50% and LV end-diastolic volume index < 97 ml/ m 2 ); and (iii) evidence of abnormal LV relaxation, filling, diastolic distensibility, and diastolic stiffness. We excluded HFpEF patients who had shown even a transient reduction in ejection fraction. Therefore, HFpEF patients whose LVEF was <50% and was improved by optimal medical therapy were not included in the present study. In our study, we stratified the ratio of E/e′ as ≥15 or >8 and <15, and BNP levels with a cutoff of 100 pg/ml.
Follow-up and cardiovascular events
Detailed follow-up and definitions of cardiovascular events are available in the Supplementary Material.
Statistical analysis
Detailed statistical analysis is available in the Supplementary Material.
RESULTS
Distribution of sK levels in HFpEF patients
A total of 506 patients with HFpEF were enrolled in this study. The distribution of sK levels on admission is shown in Supplementary Figure S1A , and sK levels at discharge are shown in Supplementary Figure S1B . The mean sK level on admission was 4.27 ± 0.43 mEq/l (median, 4.2 mEq/l; range, 4.0-4.5 mEq/l), and the mean sK level at discharge was 4.41 ± 0.44 mEq/l (median, 4.4 mEq/l; range, 4.1-4.7 mEq/l), indicating that sK levels significantly increased after optimal medical therapy for HF (P < 0.01).
Baseline clinical characteristics of HFpEF patients according to groups defined by quartiles of sK levels Table 1 shows the baseline characteristics of the HFpEF patients according to quartiles of sK levels at discharge (Q1: sK < 4.1 mEq/l, Q2: 4.1 ≤ sK <4.4 mEq/l, Q3: 4.4 ≤ sK < 4.7 mEq/l, and Q4: sK ≥ 4.7 mEq/l). Overall, the patients had a mean age of 71.7 ± 9.4 years, and 54.7% were male. The mean systolic and diastolic blood pressures were 130. was observed in the use of all drugs (loop diuretics, MRAs, RAS inhibitors, calcium channel blockers, β-blockers, and statins) among the four groups. The Q2 group showed significantly lower brachial-ankle pulse wave velocity and a lower percentage of the New York Heart Association (NYHA) classification III or IV patients than those in the Q4 group (P < 0.05, P < 0.03, respectively). Additionally, hemoglobin and the eGFR were lower, and the sNa level was higher in the Q4 group than those in the Q2 group (P < 0.01, P < 0.01, and P < 0.01, respectively).
Follow-up of HFpEF patients
Follow-up data on cardiovascular events were available for 506 HFpEF patients. The follow-up period was 0-50 months (mean, 36.7 months) and 98 cardiovascular events (19.4%) Table 1 . Baseline characteristics of heart failure with preserved ejection fraction (HFpEF) patients according to the groups defined by the quartiles of the serum potassium (sK) levels The data are the mean ± standard deviation (SD), median (interquartile range), or percentage. Abbreviations: NYHA, New York Heart Association; BP, blood pressure; baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; LVDd, left ventricular end-diastolic dimension; LAD, left atrium diameter; LVMI, left ventricular mass index; eGFR, estimated glomerular Filtration rate; BNP, B-type natriuretic peptide; MRA, mineralocorticoid receptor antagonist; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; CCB, calcium channel blocker. *P < 0.05 compared with 4.1 ≤ sK < 4.4 mEq/l. † P < 0.05 compared with 4.4 ≤ sK < 4.7 mEq/l. ‡ P < 0.05 compared with sK ≥ 4.7 mEq/l.
were recorded. No patients were lost to follow-up. Detailed cardiovascular events are shown in Table 2 . The total number of cardiovascular events and hospitalization for HF decompensation in the Q2 group were lower than those in the other groups. No significant differences were observed in the numbers of nonfatal stroke, ACS events, and cardiovascular death among the HFpEF patients according to the sK quartile groups.
Kaplan-Meier analysis in HFpEF patients according to groups defined by quintiles of sK levels
Kaplan-Meier analysis revealed that the Q2 group had the lowest probability of all cardiovascular events among the four groups (log-rank test P < 0.01 in Q4, P < 0.05 in Q1 and Q3; Figure 2A) . Additionally, the Q2 group had a lower probability of HF-related events than the other groups (logrank test P < 0.01 in Q4, P < 0.05 in Q1 and Q3; Figure 2B ). Furthermore, Q4 group had significantly higher probabilities of both cardiovascular and HF-related events compared with those in the Q1 group (log-rank test P < 0.05).
Cox proportional hazard analysis of cardiovascular events in HFpEF patients
To investigate the association between sK levels and cardiovascular events, a Cox proportional hazard model was used (Table 3) . First, significant factors of cardiovascular events were identified using a univariate Cox proportional hazards model. Next, we also constructed three forced inclusion multivariate models to determine the significance of sK levels as a continuous valuable for the prediction of future cardiovascular events. We compared the HRs of the HFpEF patients in the Q2 group (4.1 ≤ sK < 4.4 mEq/l) with those of the patients in the other sK groups. The multivariate Cox proportional hazard analysis including factors identified in the subanalysis of the I-PRESERVE trial (age, previous hospitalization for HF, DM, and ln-BNP) 8, 9 revealed that the Q1, Q3, and Q4 groups had significantly and independently higher probabilities of cardiovascular events compared with those of the Q2 group (HR = 2.39, 95% confidence interval (CI) = 1.16-4.93, P < 0.03; HR = 2.07, 95% CI = 1.02-4.21, P < 0.05; and HR = 3.54, 95% CI = 1.86-6.74, P < 0.01, respectively). Additionally, the Q2 group tended to have a lower probability of HF-related events than that of the other groups ( Figure 3 ). These findings indicated that both cardiovascular and HF-related events exhibit a J-shaped pattern in HFpEF patients.
Restricted cubic spline curve analysis of cardiovascular events in HFpEF patients
The J-shaped restricted cubic spline curve is shown in Figure 4 . The model adjusted for age, previous hospitalization for HF, DM, and ln-BNP, as in the previous Multivariate Cox proportional hazard analysis. The spline curve shows an increase in cardiovascular events for both high and low sK levels. In addition, the spline curve shows that the interval from 3.9 to 4.4 mEq/l is associated with the lowest risk of cardiovascular events.
DISCUSSIONS
With the lack of evidence in mortality reduction, according to current guidelines, 10, 11 diuretics are recommended in congested HFpEF patients who present with symptoms of volume overload to alleviate symptoms and signs. Consequently, hypokalemia, as an important complication of diuretic therapy, is frequently observed in patients with HFpEF despite the use of RAS inhibitors. Ahmed et al. 4 previously demonstrated associations between low sK levels (<4.0 mEq/l) and increased mortality in a wide spectrum of ambulatory patients with chronic mild to moderate systolic and diastolic HF. Likewise, in the present study, the Q1 group (lower than 4.1 mEq/l) had higher probabilities of cardiovascular and HF-related events than those of the Q2 group. The effect of low sK levels on cardiovascular morbidity and mortality have been reported in basic and clinical studies. 12,13 Basic studies using animal models clearly showed that low sK levels, even within the conventional range of sK, may impair not only the myocardial contractile but also the relaxation response to epinephrine, 12 and that a high-K diet could be cardioprotective at least partly by suppressing cardiac nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase-induced reactive oxygens species production. 14 We previously reported that cardiac Abbreviations: HF, heart failure; HFpEF, heart failure with preserved ejection fraction; sK, serum potassium. ‡ P < 0.05 compared with sK ≥ 4.7 mEq/l.
NADPH oxidase activation may be closely involved in the pathophysiology of HFpEF using high salt-diet-fed Dahl saltsensitive hypertensive rats, a useful animal model of HFpEF. 15 Therefore, we speculate that higher probabilities of cardiovascular and HF-related events in the Q1 group compared with those in the Q2 group in the present study were mediated in part via cardiac NADPH oxidase-induced reactive oxygen species in HFpEF patients. Moreover, low sK levels may be generally induced by (over)-use of diuretics, and the use of loop diuretics has been reported to possibility increase mortality and hospitalization in HF patients. 16 Indeed, a previous report of ours showed that the use of diuretics was independently and significantly associated with decreased sK levels in patients with cardiovascular diseases. 17 However, no significant differences were found among the four groups of HFpEF patients in the usage rate of loop or thiazide diuretics (Table 1) and in diuretic dosage (data not shown) in the present study. Although sK levels <3.5 mEq/l are clinically considered low sK levels, our findings in the present study suggested that sK levels <4.1 mEq/l may increase cardiovascular and HF-related events compared with normal sK levels between 4.1 and 4.4 mEq/l in HFpEF patients. By contrast, hyperkalemia also has serious cardiotoxic effects that can be potentially lethal, and the survival rate of CKD patients with hyperkalemia may be worse compared with that of CKD patients with normokalemia. 18 Hyperkalemia has been reported to be associated with all-cause mortality not only in patients with severe CKD 19 but also in patients with established cardiovascular disease even after adjusting for CKD stages 3-5. 5 Regarding HF, the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) trial showed that higher age, male gender, DM and serum creatinine concentration >2.0 mg/dl were the strongest predictors of hyperkalemia, but that hyperkalemia was not a significant predictor of all-cause mortality in patients with HF because of the small number of patients with advanced CKD enrolled in the trial. 20 In the present study, we also evaluated the prognosis of HFpEF patients without CKD according to quartiles and found that the prognoses of both low-sK and high-sK groups were significantly poorer compared with that of the mid-sK group (data not shown), indicating that sK levels are a significant predictor, independent of renal function in HFpEF patients. Although hyperkalemia is often observed in patients with HF due to the use of RAS inhibitors and MRAs, the usage rates of these drugs in HFpEF patients were not significantly different among the four groups in our study (Table 1) . However, only the MRA usage rate tended to be higher in the Q4 group compared with those in the other groups. Therefore, we performed an additional analysis in HFpEF patients without MRA therapy (n = 435) and found that the Q4 group (sK ≥ 4.7 mEq/l) had poorer outcomes than the Q2 group (4.1-4.4 mEq/l) (P < 0.01) (data not shown). Moreover, no drugs, including RAS inhibitors 21, 22 and MRAs, 23 have been found to improve the prognosis of HFpEF patients in large clinical trials. Therefore, we think that the poorer prognosis of the Q4 group compared with that of the Q2 group in the present study was not associated with drug regimens including MRAs in HFpEF patients.
Recently, both hypokalemia (K < 3.5 mEq/l) and hyperkalemia (K > 5.5 mEq/l) were reported to be associated with heightened risk for mortality in HFpEF patients randomized in the America (but not Russia and Georgia) as part of the TOPCAT trial. 24 This report indicated that cardiovascular risks were related to both hypokalemia and hyperkalemia respectively as well as our report, and suggested that use of MRAs in population requires careful laboratory surveillance of sK and creatinine. By contrast to this report of TOPCAT trial, we found normal sK interval between 4.1 and 4.4 mEq/l was associated with the best prognosis, and suggest that treatments for HFpEF patients target a narrower sK interval than TOPCAT trial. However, the number of patients and cardiovascular events in each quartile was rather small, as was the number of cardiovascular events in hypokalemia patients in TOPCAT. Further evaluation in a larger number of HFpEF patients is required. Furthermore, a U-shaped relationship between sK levels and mortality in patients with chronic HF, including HFpEF and HFrEF, was recently reported. 7 In this report, the risk of all-cause mortality tended to increase in HF patients with mild hyperkalemia (4.5-4.7 mEq/l), and it significantly increased in HF patients with higher sK levels (4.8-5.0 mEq/l) within the normal range (HR 1.29). Likewise, Collins et al. 25 reported mortality risk progressively increased with dyskalemia, and was differentially greater in those with HF and CKD. However, the difference of sK impact to HF between HFpEF and HFrEF remains to be poorly understood. Hence, we examined the prognosis of HFrEF (EF < 50%, n = 200) patients classified into same four groups as HFpEF patients in this study according to the quartiles of the sK levels at discharge. KaplanMeier analysis revealed that the Q1, Q2, and Q3 groups in HFrEF patients had the same probabilities of both HF-related and cardiovascular events, and only Q4 group tended to be higher probabilities of them compared with other groups (data not shown). Only in the HFpEF patients in the present study, by contrast, sK levels within the lower and upper levels of the sK range (<4.1 mEq/l and from 4.4-4.7 mEq/l, respectively) were associated with increases in both cardiovascular and HF-related events compared with the reference interval of 4.1-4.4 mEq/l. Taken together these our data, there could be some differences of sK impact to the prognosis of HF between in HFpEF and HFrEF patients. However, future clinical trials will be required to elucidate the difference of therapeutic target range of sK levels between HFpEF and HFrEF patients, and to determine if aggressive management of dyskalemia may reduce mortality in patients with HFpEF and HFrEF.
In conclusion, in patients with stable HFpEF, both low sK levels (<4.1 mEq/l) and high sK levels (>4.7 mEq/l) are common and increase the risk of cardiovascular and HF-related events, indicating a J-shaped relationship between sK levels and outcomes in HFpEF. Furthermore, sK levels within the upper level of the normal sK range (4.4-4.7 mEq/l) were also associated with a significant increase in cardiovascular events compared with the reference interval of 4.1-4.4 mEq/l. To the best of our knowledge, this is the first report of the longterm effects of sK levels on cardiovascular and HF-related Adjustment for other confounders (hazard ratio=1 set at reference 4.1 ≤ sK < 4.4 mEq/l). Model 1: age, previous hospitalization for HF, diabetes mellitus, Ln-BNP and sK (Q1-Q4); Model 2: previous hospitalization for HF, atrial fibrillation, chronic kidney disease, LAD, E/e′, LVMI, hemoglobin, Ln-BNP, serum sodium and sK (Q1-Q4); Model 3: loop or thiazide diuretics, MRA, β-blockers, and sK (Q1-Q4). Abbreviations: Ln-BNP, natural logarithmic transformed B-type natriuretic peptide level; LAD, left atrium diameter; LVMI, left ventricular mass index; MRA, mineralocorticoid receptor antagonist; HFpEF, heart failure with preserved ejection fraction; sK, serum potassium; CI, confidence interval. events in chronic HFpEF patients. Our data could suggest that we should treat chronic HFpEF patients to keep the sK within a relatively narrow range (4.1-4.4 mEq/l) with optimal medical therapy even by using potassium-chelating or supplementation agents, and/or adjusting the dosages of diuretics and RAS inhibitors including MRAs.
STUDY LIMITATIONS
The present study has some limitations. First, it was a single-center design with a small patient population. Therefore, a larger multiracial, multicenter study is required. Second, although the present study showed increased cardiovascular and HF-related events in the Q1 group, we had no detailed data on arrhythmogenic events and sudden cardiac death. Many previous reports have shown that low sK levels may cause arrhythmia and sudden death in HF patients, 26, 27 therefore, fatal arrhythmias and sudden cardiac death could also be increased in HFpEF patients. Third, the group with the worst prognosis had a significantly worse renal function. Therefore, the possibility that a poor prognosis is associated with a decline in renal function rather than an electrolyte imbalance could not be ruled out. The specific factors influencing the association between sK levels and cardiovascular risks are unclear, and the extent to which these factors may contribute to the relationships of both sK levels and the promotion of malignant cardiovascular risks is unknown. Therefore, further pathophysiological and molecular physiological studies, including animal experiments, are warranted.
CONCLUSIONS
Despite these limitations, we demonstrated that sK levels were significantly and independently correlated with the occurrence of future HF-related events in HFpEF patients. Figure 3 . Cox hazard analysis of cardiovascular events and heart failure (HF)-related events. The plot shows the hazard ratios and 95% confidence intervals (CI) for cardiovascular events and HF-related events associated with serum potassium (sK) levels in patients with heart failure with preserved ejection fraction (hazard ratio = 1 set as the reference Q2: 4.1 ≤ sK < 4.4 mEq/l). The model is adjusted for age, previous hospitalization for HF, diabetes mellitus, and natural logarithmic transformed B-type natriuretic peptide level. 
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